Biologics development and manufacturing
Get to clinical trials faster
Our technologies and services help expedite and streamline biologics development—improving yield with expression and purification services; helping prepare for clinical trials with ICH stability profiles; meeting safety standards with endotoxin detection and removal; and manufacturing at our GMP facility.
Soluble Biotech is now Predictive Oncology.
Protein expression & purification
We offer prokaryotic and eukaryotic protein expressions, including bacterial expression, CHO/HEK expression and production of membrane proteins.
Endotoxin detection & removal
Most chromatography ligands are non-specific and result in incomplete removal and/or significant loss of product. Our endotoxin removal technology is superior to existing products because it binds both ends of the endotoxin contaminants, thus increasing the amount removed from the media.
Analytical development
Our full range of analytical techniques determine a drug's stability profile with respect to solubility, chemical modification, subvisible particles, thermal stability and photostability.
What can biologics development do for you?
Our thorough protein expression and purification services can help you improve yield, while endotoxin removal products and services help you efficiently meet safety standards. Finally, our efficient ICH stability profiles help better prepare for clinical trials.
After a formulation is identified, the FDA requires long-term stability testing and thorough endotoxin removal to progress candidate drugs to human clinical trials. We provide a full range of long-term stability tests to help pharmaceutical companies progress their biologic candidates to clinical trials.
At our GMP facility we manufacture high-quality endotoxin detection and removal products to use in your process. We follow GMP, ICH and GLP standards throughout to ensure consistent and standardized products and services.
Talk to us about biologics development today.
Complete the form and we’ll be in touch to discuss customized solutions for your needs.


News & resources
Dominic Pollard of Cancer Research Horizons and Dr. Pamela Bush of Predictive Oncology discuss the potential impact of their collaboration and how it can advance...
Cancer Research Horizons to incorporate PEDAL into future drug discovery processes to enable drug development on a global scale 11 marketed drugs 2nd largest oncology...
Proactive Investor’s Natalie Stoberman met with Raymond F. Vennare, CEO of Predictive Oncology, and Javier Torres-Roca, MD, Co-Founder and CEO of Cvergenx, Inc., to discuss...